Skip to main content

Application of Nanotechnology in Modified Release Systems

  • Chapter
  • First Online:
Pharmaceutical Nanotechnology

Abstract

The most appropriate route of administration is considered to be oral, because of the patient compliance and of economical issues. Drug delivery nanosystems are defined as technological platforms that promote the effective administration of bioactive molecules or therapeutic agents (protein, peptide, antibody, genetic material) in the human organism. Drug delivery nanosystems have been evaluated based on their physicochemical and structural properties and on the way that they behave within biological media. They are developed to optimize the production of new medicines, to ameliorate patient compliance, and to improve their targetability from systemic to specific tissues and cells. Hybrid and chimeric drug delivery nanosystems are two major classes that are categorized based on the nature of the mixing biomaterials to produce the final nanocarrier. Their ability to mimic the functions of natural objects proceeds to the category of bio-inspired drug delivery systems.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alvarez-Lorenzo C, Conheiro A (2013) Bio-inspired drug delivery systems. Curr Opin Biotechnol 24:1–7

    Article  Google Scholar 

  2. Beck A, Reichert JM (2014) Antibody-drug conjugates: present and future. MAbs 6(1):15–17

    Article  PubMed  Google Scholar 

  3. Bouchard H, Viskov C, Garcia-Echeverria C (2014) Antibody-drug conjugates—a new wave of cancer drugs. Bioorg Med Chem Lett 24(23):5357–5363. doi:10.1016/j.bmcl.2014.10.021.

    Google Scholar 

  4. Bushman J, Vaugham A, Sheihet L et al (2013) Functionalized nanospheres for targeted delivery of paclitaxel. J Control Release 171(3):315–321

    Article  CAS  PubMed  Google Scholar 

  5. Chang TMS (1979) Artificial cells as drug carriers in biology and medicine. In: Gregoriadis G (ed) Drug carriers in biology and medicine. Academic, London, pp 271–285

    Google Scholar 

  6. Crommelin DJ, FFlorence AT (2013) Towards more effective advanced drug delivery systems. Int J Pharm 454:496–511

    Article  CAS  PubMed  Google Scholar 

  7. Demetzos C (2008) Differential scanning calorimetry (DSC): a tool to study the thermal behavior of lipid bilayers and liposomal stability. J Liposome Res 18:159–173

    Article  CAS  PubMed  Google Scholar 

  8. Demetzos C (2015) Biophysics and thermodynamics: the scientific blocks of bio-inspired drug delivery nano systems. AAPS PharmSciTech 16(3):491–495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Demetzos C, Pippa N (2014) Advanced drug delivery nanosystems (aDDnSs): a mini review. Drug Deliv 21(4):250–257

    Article  CAS  PubMed  Google Scholar 

  10. Emshanova SE (2008) Drug synthesis methods and production technologies, methodological approaches to the selection of excipients for preparation tablets by direct pressing. Pharm Chem J 42(2):89–94

    Article  CAS  Google Scholar 

  11. Feng Y, Zhu Z, Chen W et al (2014) Conjugates of small molecule drugs with antibodies and other proteins. Biomedicines 2:1–13. doi:10.3390/biomedicines2010001

    Article  Google Scholar 

  12. Gardikis K, Hatziantoniou S, Bucos M et al (2010) New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal-locked in dendrimers) for cancer therapy. J Pharm Sci 99(8):3561–3571

    Article  CAS  PubMed  Google Scholar 

  13. Gardikis K, Hatziantoniou S, Signorelli M et al (2010) Thermodynamics and structural characterization of liposomal locked-in dendrimers as drug carriers. Colloids Surf B Biointerfaces 81(1):11–19

    Article  CAS  PubMed  Google Scholar 

  14. Gardikis K, Tsimplouli C, Dimas K et al (2010) New chimeric advanced drug delivery nanosystems (Chi-aDDnSs) as doxorubicin carriers. Int J Pharm 402(1–2):231–237

    Article  CAS  PubMed  Google Scholar 

  15. Gregoriadis G (2008) Liposome research in drug delivery, the early days. J Drug Target 16(7):520–524

    Article  CAS  PubMed  Google Scholar 

  16. Gupta H, Bhandari D, Sharma A (2009) Recent trends in oral drug delivery: a review. Recent Patents Drug Deliv Formulation 3(2):162–173

    Article  CAS  Google Scholar 

  17. Heimburg T (2007) Thermal biophysics of membranes. Wiley –Vott, Weinheim

    Book  Google Scholar 

  18. Khopade AJ, Caruso F, Tzipathi P, Nagaich S, Jain NK (2002) Effect of dendrimer on entrapment and release of bioactive from liposome. Int J Pharm 232(1–2):157–162

    Article  CAS  PubMed  Google Scholar 

  19. Kiparissides C, Kammona O (2008) Nanotechnology advances in controlled drug delivery systems. Phys Stat Sol 5(12):3828–3833

    Article  CAS  Google Scholar 

  20. Lianos GD, Vlachos K, Zoras O et al (2014) Potential of antibody-drug conjugates and novel therapeutics in breast câncer management. Onco Targets Ther 7:491–500

    PubMed  PubMed Central  Google Scholar 

  21. Lin Y, Mao C (2011) Bio-inspired supramolecular self-assembly towards soft nanomaterials. Front Matter Sci 5(3):247–256

    Article  Google Scholar 

  22. Mourelatou EA, Libster D, Nir I et al (2011) Type location and interaction between hyperbranched polymers and liposomes. Relevance to design of potentially advanced drug delivery nanosystem (aDDnSs). J Phys Chem B 115(13):3400–3408

    Article  CAS  PubMed  Google Scholar 

  23. O’ Neil GJ (1979) The use of antibodies as drug carriers. In: Gregoriadis G (ed) Drug carriers in biology and medicine. Academic, London, pp 23–41

    Google Scholar 

  24. Ornes S (2013) Antibody-drug conjugates. Proc Natl Acad Sci U S A 110(34):13695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Papachristos A, Pippa N, Demetzos C et al (2015) Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines. Drug Deliv, in press

    Google Scholar 

  26. Papagiannaros A, Dimas K, Papaionannou GT, Demetzos C (2005) Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int J Pharm 302:29–38

    Article  CAS  PubMed  Google Scholar 

  27. Peppas NA (2013) Historical perspective on advanced drug delivery: how engineering design and mathematical modeling helped the field nature. Adv Drug Deliv Rev 65(1):5–9

    Article  CAS  PubMed  Google Scholar 

  28. Pippa N, Gardikis K, Pispas S et al (2014) The physicochemical/thermodynamic balance of advanced drug liposomal delivery systems. J Therm Anal Calorim 116:99–105

    Article  CAS  Google Scholar 

  29. Pippa N, Merkouraki M, Pispas S et al (2013) DPPC:MPOx chimeric advanced drug delivery nanosystems (chi-aDDnSs): physicochemical and structural characterization, stability and drug release studies. Int J Pharm 450(1–2):1–10

    Article  CAS  PubMed  Google Scholar 

  30. Pippa N, Kaditi E, Pispas S et al (2013) PEO-b-PCL: DPPC chimeric nanocarriers: self – assembly aspects in aqueous and biological media and drug incorporation. Soft Matter 9:4073–4082

    Article  CAS  Google Scholar 

  31. Rowland M, Noe CR, Smith DA et al (2012) Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years. J Pharm Sci 101:4075–4099

    Article  CAS  PubMed  Google Scholar 

  32. Sapra P, Betts A, Boni J (2013) Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. Expert Rev Clin Pharmacol 6(5):541–554

    Article  CAS  PubMed  Google Scholar 

  33. Saroglou V, Hatziantoniou S, Smyrniotakis M et al (2006) Synthesis liposomal formulation and thermal effects on phospholipid bilayers of leuprolide. J Peptide Sci 12(1):43–50

    Article  CAS  Google Scholar 

  34. Stazz C (2000) Innovation in drug delivery. Patent Care 15:107–137

    Google Scholar 

  35. Shefet-Carasso L, Benhar I (2014) Antibody-targeted drugs and drug resistance-challenges and solutions. Drug Resist Updat 18:36–46

    Article  PubMed  Google Scholar 

  36. Tiwari G, Tiwari R, Sriwastawa B et al (2012) Drug delivery systems: an updated review. Int J Pharm 2(1):2–11

    Google Scholar 

  37. Yoo JW, Irvine JD, Discher DE et al (2011) Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 10:521–535

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Appendices

Appendix

1.1 Thermodynamics of Innovative Drug Delivery Nanosystems

Calorimetry is a technique that can be used to measure the heat capacity of a material with a well-defined mass. It is also used to determine thermal effects that occur in physical, chemical, and biological processes. It is of interest that changes of enthalpies in mixed materials such as biological objects or biomaterial-formed nanoparticles are issued to the field of calorimetry.

Thermodynamics is considered as a basic element in physics, and thermal analysis is used to determine the thermal effects of materials and biomaterials, and it is considered as one of the most popular techniques in material sciences and engineering [17]. There are a numerous thermoanalytical techniques (see Chap. 2) which can provide information such as polymorphism, stability, interactions, and physical purity of biomaterials or of self-assembled nanostructures such as liposomes, micelles, and nanoparticles (Gardikis et al. [13]). There are several applications that can be considered as very helpful in order to establish the behavior of biomaterials and of nanostructures. We can point out that processes such as melting, polymorphism, purity vaporization, glass transition, compatibility between different biomaterials in nature, etc. are highly related to the field of thermodynamics. Supramolecular structures at nanoscale level are very promising and can be used in drug delivery in imaging and in diagnosis. The biophysics and thermodynamics are considered as scientific building blocks for evaluating drug delivery systems [8]. Biophysics is a valuable element in order to explain the orientation and reorientation process of a nanosystem taking into account the external environmental parameters, and it is also used to understand the organization of nanostructures comparing their behavior with that of living organisms. It is well established that different phases such as cubic, hexagonal, inverse hexagonal, etc. can be produced depending on the physical micro- and macro-environment parameters such as temperature, ionic strength, pH, osmolarity, and concentration of lipids to be used for producing liposomal bilayers. The aforementioned changes can be directly correlated with physicochemical and biophysical behavior of liposomes as drug delivery systems, such as kinetics in drug release, stability, surface functionality, etc.

The melting process of lipidic drug delivery nanosystems, i.e., liposomes, affects the behavior of lipidic membranes and induces events leading to transitions and creation of metastable phases (see Chap. 2). Thermodynamics is considered as a basic element in physics, and thermal analysis is used to determine the thermal effects of materials and biomaterials, and it is considered as one of the most popular techniques in material sciences and engineering. There are a numerous thermoanalytical techniques (see Chap. 2) which can provide information such as polymorphism, stability, interactions, and physical purity of biomaterials or of self-assembled nanostructures. The naturally occurring infrastructures are composed of different nature biomaterials such as hydrocarbons, proteins, lipids, etc., and this could be an efficient model that can promote artificial structures and strategies in order to develop innovative drug delivery nanosystems. By combining different nature biomaterials such as lipid and polymers, chimeric artificial supramolecular structures can be built up (see Chap. 5) [14]. Their thermodynamic profile contributes to the development process and to study their equilibrium states by passing from one metastable phase to another. The steady state is almost eliminated and their organization profile promotes their functionality and can be related with their stability. A Gibbs free energy difference, Δ (ΔG), is an appropriate thermodynamic parameter to initiate the equilibrium state in innovative mixed in nature bilayer between different membrane segments of different curvatures. This attributes to a high involvement of thermodynamics in studying and measuring the transitions between lipidic phases. The formation of lipidic vesicles has been extensively studied by researchers mainly in the field of colloidal science, and the polymorphism of phospholipids seems to play a key role because of its relation with the geometrical characteristics of liposomal vesicles. The geometrical aspects and the thermodynamics and their compromise relationship are under investigation especially with those vesicles that are categorized as chimeric drug delivery nanosystems (Chap. 5). The metastable phases are considered as important element in order to realize the thermal behavior of lipidic bilayers. The lipid-water systems can create lipidic phases with predominant lamellar phases, depending on the lipid concentration. Liposomes belong to drug delivery nanosystems and are characterized as lyotropic liquid crystals (see Chap. 4). The conformational polymorphism of their lipidic bilayers is responsible for the mesophases, i.e., metastable phases, taking place in phase transitions and is related to their thermal stress during phase transitions. Their thermal stress takes place during liposome dispersion system storage or during administration in humans. The thermodynamic parameters that affect and participate in physical stability and, therefore, in pharmaceutical effectiveness of the liposomal product are as follows: Tm, temperature of basic transition from liquid crystalline phase to isotropic fluid; ΔT 1/2, the phase transition range in the middle of the peak (this temperature range is related to the cooperativity of system phospholipids or phospholipids and enclosed bioactive molecule); ΔΗ, system enthalpy change; and ΔCp, system thermal capacity change under constant pressure. The identification and study of these mesophases of liposomal nanosystem lipid bilayers allow the control over the thermodynamic parameters mentioned above, in order to rationally design the liposomal system with the most satisfactory physical and thermal stability [7].

Thermal techniques are considered as valuable to study the thermal behavior of the conformational polymorphism (i.e., metastable phases) of drug delivery nanosystems, such as liposomes, while they are used to evaluate the physicochemical properties of drugs and their interactions in in vitro biological media, as well as their behavior during the formulation process [28]. The regulatory issues concerning the design and the development of innovative drug delivery nanosystems involve a combination of valuable techniques for structural and thermodynamic characterization in order to completely delineate the physicochemical/thermodynamic balance [28].

From the regulatory point of view, thermal analysis can provide rational approaches to fully characterize delivery nanosystems that could be applied in pharmaceutics, adopting the thermodynamics in the evaluation of the development process of medicines.

Summary

Innovative drug delivery nanosystems are classified as hybrid and as chimeric in order to facilitate their studies based on biophysical and thermodynamic aspects. The above terms are the evolution of the Liposomal Lock in Dendrimers (LLDs).

The metastable phases of hybrid and chimeric nanoparticulate systems determine their stability, release of the incorporated bioactive molecule, and functionality and can translate the cooperativity of their building elements and their biophysical behavior based on the origin of the biomaterials that they are composed of.

The innovation profile of bio-inspired drug delivery nanosystems is based on their ability to mimic the function of natural objects. Moreover, their fabrication process could adapt various aspects that nature use to build up high-performance biological units.

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Demetzos, C. (2016). Application of Nanotechnology in Modified Release Systems. In: Pharmaceutical Nanotechnology. Adis, Singapore. https://doi.org/10.1007/978-981-10-0791-0_5

Download citation

Publish with us

Policies and ethics